Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Ryan

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Blood Advances|January 10, 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood Advances|October 6, 2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and activeJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2022
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic MalignancyJing Deng, Aneel Paulus, Douglas D Fang, et al.
Nature Communications|August 4, 2019
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancerMarcel A Dammert, Johannes Brägelmann, Rachelle R Olsen, et al.
Cancer Discovery|December 19, 2013
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemiaRongqing Pan, Leah J Hogdal, Juliana M Benito, et al.
Molecular Cancer Research : MCR|August 30, 2019
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian CancerElizabeth H Stover, Maria B Baco, Ofir Cohen, et al.
Nature|January 7, 2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Charles Y Lin, Housheng Hansen He, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Blood Advances|January 10, 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood Advances|October 6, 2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and activeJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2022
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic MalignancyJing Deng, Aneel Paulus, Douglas D Fang, et al.
Nature Communications|August 4, 2019
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancerMarcel A Dammert, Johannes Brägelmann, Rachelle R Olsen, et al.
Cancer Discovery|December 19, 2013
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemiaRongqing Pan, Leah J Hogdal, Juliana M Benito, et al.
Molecular Cancer Research : MCR|August 30, 2019
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian CancerElizabeth H Stover, Maria B Baco, Ofir Cohen, et al.
Nature|January 7, 2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Charles Y Lin, Housheng Hansen He, et al.
Pageof 7